HEARTFLOW INC (HTFL)
Health Care · medical diagnostics / software · NASDAQ
HeartFlow develops non-invasive, AI-powered diagnostic software that helps physicians evaluate coronary artery disease using patient-specific 3D heart models.
What HEARTFLOW INC does
HeartFlow provides non-invasive, AI-driven diagnostic software for the evaluation of coronary artery disease (CAD). Its primary platform uses data from coronary CT angiography to create personalized 3D models of a patient's coronary arteries, allowing physicians to evaluate the functional impact of suspected blockages. The company is currently focused on the commercialization of its HeartFlow FFR CT Analysis and HeartFlow Plaque Analysis products.
Themes: AI diagnostics, cardiovascular health, medical imaging software, coronary artery disease (CAD) management
Fundamentals
- Price$49.75 as of 2026-08-21 close
- Market cap$4.3B as of 2026-08-21
- 1-year return+72.0% 2025-08-21 close $28.93 → 2026-08-21 close $49.75
- P/En/a negative earnings
- Net margin-58.4% as of 2026-08-24
- Gross margin+78.1% as of 2026-08-24
- ROE-38.9% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+41.3% as of 2026-08-24
- Revenue CAGR (3y)+42.1% SEC XBRL
- Beta2.15 as of 2026-08-24
- Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)
How HTFL compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
HTFL is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
50.5 #744 of 1,704 scored · #132 of 240 in Health Care
Volume and participation 96th: it gapped 26.0% above the previous close and has not traded back through the level it left behind — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed; trend 82nd: it is trading 62.0% above its 50-day average, the short-term trend line; weakest is setup 17th: day-to-day price swings are unusually wide versus its own recent history (wider than about 99% of the past ~6 months). Its score is docked 10 points for overextended (RSI above 75 or stochastic above 90).
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How HEARTFLOW INC looks technically
HEARTFLOW INC (HTFL) is trading 68.7% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 5 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 42, with buyers in control. Momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 88, in overbought territory (above 70). It just made a new 20-day high, pushing above its recent trading range. It is 1.4% below its all-time high.
Trend
8
| Distance from the 200-day | it is trading 68.7% above its 200-day average, the long-term trend line — a longer-term uptrend | +68.7% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $30.70 | $30.70 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $29.48 | $29.48 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 30 calendar days ago — the swings before that are what the structure reading is measured on | 30 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 5 trading days ago — a "golden cross", a bullish long-term signal | 5 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 68.7% above | +68.7% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 42, with buyers in control | 42.2 |
Momentum
3
| 14-day RSI | momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 88, in overbought territory (above 70) | 88.5 |
|---|---|---|
| Position in its 14-day range | it is trading right at the top of its 14-day range ($26.54 to $50.48) — its "stochastic" reading is 97 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 97.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 18 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $50.48 | $50.48 |
|---|---|---|
| From the 52-week high | it is 1.4% below its 52-week high (its highest price of the past year) | -1.4% |
| Above the 52-week low | it is 147.1% above its 52-week low (its lowest price of the past year) | +147.1% |
| Below the 52-week high | it is 1.4% below its highest point of the past year | 1.4% |
| Since a 20-day breakout | it just made a new 20-day high, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $50.48 (set on 2026-08-21) | $50.48 |
| Given back of the 52-week move | over the past year its closes ranged ($20.49 to $49.75), and it has given back essentially none of its rise from last year’s low — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $30.73 to $31.67. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.0% |
| From the all-time high | it is 1.4% below its all-time high | -1.4% |
| Nearest price level | not enough price history yet — needs 252 trading sessions | n/a |
| All-time low | its lowest closing price on record is $20.13 (set on 2026-02-13) | $20.13 |
| Above the all-time low | it is 147.1% above its all-time low | +147.1% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 99% of the past ~6 months) | 99th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.61 between its high and its low — about 5.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.61 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $15.90 and $49.64 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $15.90 – $32.77 – $49.64 |
| Typical daily range (% of price) | its price moves about 5.3% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.3% |
| Stretch from the 200-day average | it is trading 7.8 daily ranges above its 200-day average price (68.7% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 7.8 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.51× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 18.8% since the prior reading | +18.8% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has softened toward "sell" since the prior reading | 0.06 toward sell |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.2% |
|---|---|---|
| Open gap | it gapped 26.0% above the previous close 5 sessions ago and has not traded back through the level it left behind at 31.01 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +26.0% |
| Gap filled | a 2.4% gap up opened on 2026-07-31 has been "filled" 15 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 15 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 4 sessions in a row, a +18.62% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 4 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 93.2 percentage points (the stock gained 95.6% while the market gained 2.3%) | +93.2% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 67.3 percentage points (the stock gained 70.4% while the market gained 3.1%) | +67.3% |
| vs market, 6 months | over the past 6 months this stock beat the market by 87.1 percentage points (the stock gained 98.2% while the market gained 11.1%) | +87.1% |
| vs market, 12 months | over the past 12 months this stock beat the market by 51.5 percentage points (the stock gained 72.0% while the market gained 20.5%) | +51.5% |
Signal agreement
2
| Bullish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: its RSI momentum gauge is overbought (a stretched reading), near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 63% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 3.3% of the share price. | +62.5% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 66% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $30.02 — a volume-weighted average of daily closes over 150 sessions, not a true tick-by-tick VWAP. | +65.7% |
|---|
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Tested and reclaimed 200-day support · Overbought (14-day RSI above 70) · Near the 52-week high · Broke out to a new 20-day high | Learn: moving average · golden cross · adx · rsi · breakout · all time high
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.50 mean, 1=Strong Buy…5=Strong Sell) — 8 analysts
- Mean price target$43.50 range $39.00 – $45.00; median $45.00
Analyst estimates, as of 2026-08-21. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for HTFL
- Consensus EPS estimate-$0.1046 next reporting period, as of 2026-08-21
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Highly dependent on the commercial success of a very limited product portfolio (FFR CT and Plaque Analysis).","Significant, recurring net losses with no guarantee of achieving or sustaining future profitability.","Dependency on third-party payors, including government programs, for coverage and adequate reimbursement levels."]
What changed in the latest 10-Q
AI-assisted comparison of HTFL's 10-Q filed 2026-05-14 against the prior one filed 2025-11-12.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing references Annual Report on Form 10-K filed March 18, 2026, whereas older filing references registration statement on Form S-1 effective August 7, 2025
- Newer filing states Heartflow Platform used to assess CAD in more than 650,000 patients as of March 31, 2026, including 219,000 in 2025 alone
- Newer filing identifies four software products developed (Heartflow RoadMap Analysis, Heartflow FFR CT Analysis, Heartflow Plaque Analysis, and Heartflow PCI Navigator)
- Newer filing states Heartflow PCI Navigator was recently launched in April 2026
- Newer filing anticipates launching Plaque Tracker as fifth product in 2027
- Newer filing lists Saudi Arabia, United Arab Emirates, and Bahrain as markets with medical device licensing or approvals
- Newer filing states Heartflow FFR CT Analysis represents 98% of total cumulative revenue as of March 31, 2026
- Newer filing indicates Heartflow Plaque Analysis is currently covered by five of seven MACs with remaining MACs providing coverage on case-by-case basis
- Newer filing reports Q1 2026 revenue of $52.6 million (three months ended March 31, 2026 vs 2025)
- Newer filing states cash position of $254.9 million as of March 31, 2026
- Removed:
- Older filing stated three software products developed with fourth product expected to launch in 2026
- Older filing referenced Heartflow PCI Planner expected to launch in 2026
- Older filing listed regulatory approval in Australia and Canada in existing commercial presence section
- Older filing stated total revenue represented 98% for Heartflow FFR CT Analysis as of September 30, 2025
- Older filing indicated Heartflow Plaque Analysis covered by certain government and third-party payors
- Older filing reported Q3 2025 revenue of $46.3 million and nine-month revenue of $126.9 million
- Older filing stated cash and cash equivalents of $291.2 million as of September 30, 2025
- Older filing detailed January and March 2025 issuance of $98.3 million in 2025 Convertible Notes
- Reworded:
- Removed 'pioneered the use of' from opening description, replaced with 'provide'
- Changed product name from 'Heartflow PCI Planner' to 'Heartflow PCI Navigator'
- Changed product launch status from 'expect to launch in 2026' to 'recently launched in April 2026'
- Added language that Heartflow PCI Navigator is provided 'to accounts as an integrated feature' with similar phrasing to other products
- Expanded regulatory approval listing to include Saudi Arabia, United Arab Emirates, and Bahrain in newer filing
- Changed 'certain government and third-party payors' to more specific 'five of the seven MACs with the remaining MACs providing coverage on a case-by-case basis and by a majority of commercial payors'
- Notes:
- The newer filing text appears truncated at the end ('The cash proceeds fro'), limiting ability to assess complete changes in IPO-related disclosures
- Comparison period differs between filings (Q1 2026 vs Q3 2025 for the newest quarterly data), making some metric comparisons reflect different time periods
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 4 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 4 sells ($3M) — 2 selling insiders
- Last 180 days0 buys · 11 sells ($63M) — 3 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-15. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about HTFL's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding HTFL as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 8,079,641
- Reported value $196,577,680
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
HTFL had 6,847,694 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
HTFL had 7.88% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 6.61 days to cover at the same settlement.
- Reported short interest (shares) 6,847,694
- Short interest (% of shares outstanding) 7.88%
- Prior settlement (shares) 5,873,437
- Reported change 16.59%
- Days to cover (reported) 6.61
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
HTFL ranks in…
Frequently asked questions
What does HEARTFLOW INC (HTFL) do?
HeartFlow provides non-invasive, AI-driven diagnostic software for the evaluation of coronary artery disease (CAD). Its primary platform uses data from coronary CT angiography to create personalized 3D models of a patient's coronary arteries, allowing physicians to evaluate the functional impact of suspected blockages. The company is currently focused on the commercialization of its HeartFlow FFR CT Analysis and HeartFlow Plaque Analysis products.
What sector is HEARTFLOW INC (HTFL) in?
HEARTFLOW INC (HTFL) is classified in the Health Care sector. Its industry is medical diagnostics / software. It trades on NASDAQ.
Is HEARTFLOW INC (HTFL) overbought or oversold right now?
HEARTFLOW INC (HTFL) is currently in overbought territory (its 14-day RSI is 88, above 70) (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on HTFL come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.